Italia markets close in 6 hours 6 minutes
FTSE MIB
33.844,63 +108,23 (+0,32%) Dow Jones
38.225,66 +322,37 (+0,85%) Nasdaq
15.840,96 +235,48 (+1,51%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
78,95 0,00 (0,00%) Bitcoin EUR
55.280,34 +1.478,47 (+2,75%)
Neurocrine Biosciences, Inc. (NB3.F)
Frankfurt - Frankfurt Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
In data: 10:16AM CEST. Mercato aperto.
| Chiusura precedente | 134,80 |
| Aperto | 129,65 |
| Denaro | 129,55 x 50000 |
| Lettera | 130,50 x 50000 |
| Min-Max giorno | 129,65 - 130,95 |
| Intervallo di 52 settimane | 83,18 - 135,35 |
| Volume | |
| Media Volume | 14 |
| Capitalizzazione | 13,178B |
| Beta (5 anni mensile) | 0,28 |
| Rapporto PE (ttm) | 38,07 |
| EPS (ttm) | 3,44 |
| Prossima data utili | 30 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 122,19 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.